Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00204529
Status:
COMPLETED
Last Update Posted:
2017-05-03
First Post:
2005-09-12
Brief Title:
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Randomized Multicenter Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 PEG-IFN to Low-dose Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA T3a - IIIB AJCC 2002
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a PEG-IFN vs low dose interferon-α-2a in patients with malignant melanoma in stage IIA T3a - IIIB
A total of 880 will be randomized up to three months after first surgical management of their melanoma to either PEG-IFN-α-2a or low-dose interferon-α-2a
A total of 880 will be randomized up to three months after first surgical management of their melanoma to either PEG-IFN-α-2a or low-dose interferon-α-2a
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None